The new facility (6 filling lines, for liquid and lyophilized injectable product), will handle IMMUNONCOLOGY DRUGS, IMMUNOTHERAPY DRUGS, as well as other INNOVATIVE PRODUCTS, with the objective to meet the needs of innovators in a wide range of therapeutic indications. The plant will be available for DP (Drug Product) manufacturing of small and large molecules as:
